PRX-115

Protein / enzyme therapeutic

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Company guidance: topline data expected second half of 2027 (Protalix BioTherapeutics, Inc., 12 Aug 2026). “● PRX-115 Phase 2 study continues to advance as planned, with top-line results anticipated in the second half of 2027” Source ↗

Company guidance: topline data expected second half of 2027 (NCT07280156; Protalix BioTherapeutics, Inc., 10 Nov 2026). “● The PRX-115 Phase 2 RELEASE study remains on track, aiming to improve adherence and durability of response in uncontrolled gout, a substantial unmet need; top-line results anticipated in the second half of 2027” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Phase 1 (1)
Other / comorbidity

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow PRX-115 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 2GoutRecruiting
Est. primary completion 2027-12 · NCT07280156 · CT.gov ↗

Company guidance: topline data expected second half of 2027 (Protalix BioTherapeutics, Inc., 10 Nov 2026). “● The PRX-115 Phase 2 RELEASE study remains on track, aiming to improve adherence and durability of response in uncontrolled gout, a substantial unmet need; top-line results anticipated in the second half of 2027” Source ↗

What to watch

See the full readout calendar ↗